Combinatorial Targeting of Prostate Carcinoma Cells and Tumor Associated Pericytes with Antibody-Based Immunotherapy and Metronomic Chemotherapy
Abstract
Seventy seven 10 week old TRAMP mice were enrolled in the study. Administration of metronomic chemotherapy with cyclophosphamide and AN2 crossreacting mAb 225.28 or isotype control mAb F3- C25 was well tolerated. The therapy reduced disease burden and the severity of the disease. The findings from these studies support development of metronomic chemotherapy for the treatment of progressive disease (men with a rising PSA), aggressive forms of the disease and castration recurrent disease.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2011
- Accession Number
- ADA551786
Entities
People
- Barbara A Foster
- Michael Moser
- Soldano Ferrone
Organizations
- University of Pittsburgh